Journal Article

Dialysis-related amyloidosis: importance of biocompatibility and age.

M Jadoul

in Nephrology Dialysis Transplantation

Volume 13, issue suppl_7, pages 61-64
Published in print January 1998 | ISSN: 0931-0509
Published online January 1998 | e-ISSN: 1460-2385 | DOI:
Dialysis-related amyloidosis: importance of biocompatibility and age.

Show Summary Details


The histological prevalence of dialysis-related amyloidosis (DRA) is much greater than suspected on clinical grounds: one-third of patients are affected after less than 4 years on haemodialysis (HD) and over 90% after more than 7 years HD. Risk factors include the time on dialysis, the type of HD membrane, and the age of the patient at onset of dialysis. The protective effect of high-flux membranes such as AN69 probably results mainly from the greater clearance of beta2-microglobulin. Other potential but more controversial explanations include a protective influence on residual renal function, a lower stimulation of beta2-microglobulin synthesis or release, or a beneficial influence on advanced glycosylation end (AGE) products. The higher risk of DRA in older patients has recently been suggested to result from an age-related AGE-modification of osteoarticular collagen. The best prevention and treatment of DRA is successful renal transplantation. In patients unsuitable for transplantation, high flux membranes such as AN69 should be used from the start of dialysis. Palliative treatment includes analgesics, low dose prednisone in severe cases, and surgical treatment of complications.

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.